NCGC00138783 (TFA)
NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC50 of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis[1][2].
Product Specifications
UNSPSC
12352005
Target
CD47
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ncgc00138783-tfa.html
Purity
99.38
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(C(F)(F)F)O.CCC(C(NC1=CC=C(C=C1)F)=O)SC2=NC3=C(C4=NC(CCC5=C(NN=C5C)C)=NN24)C=CC=C3
Molecular Formula
C28H27F4N7O3S
Molecular Weight
617.62
References & Citations
[1]Junqiao Zhu, et al. CD47-SIRPα axis in cancer therapy: Precise delivery of CD47-targeted therapeutics and design of anti-phagocytic drug delivery systems. Medicine in Drug Discovery. 2022. 15:100139|[2]Bo Huang, et al. Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy. Comput Struct Biotechnol J. 2021 Oct 1;19:5494-5503.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
